Podcasts about himalaya

Al Burgess reads wild stories of 1980s alpinism and all that that world entailed - fighting for your life and passing into death.

Dr Kelley discusses standard first-line treatment options for patients with advanced HCC, key findings from the phase 3 HIMALAYA trial, and the safety profile of the STRIDE regimen in this population.

For Alan Rousseau, the allure of mountaineering is in the unknown. When he looks up at a mountain and contemplates whether it can be climbed, he sees a mystery to be solved.  Rousseau is an IFMGA guide who divides his time between pursuing his own goals in the mountains, and helping others do the same. His achievements in the Alaska Range, to which he has ventured more than twenty times, include first ascents of Ruth Gorge Grinder and Aim for the Bushes. In 2020, his first ascent of the west face of Tengi Ragi Tau with Tino Villanueva was recognized as one of the year's greatest climbing achievements and the pair won a Piolets d'Or. Villanueva wrote about the climb in Alpinist 81.  In this episode, Alan reflects on more than ten years of climbing in the Alaska Range, and exploratory climbs like Aim For the Bushes that he and his partners established earlier this year. He talks about the difference between planning trips to Alaska and the Himalaya, and the mountains that act as his compass. This episode is brought to you by the American Alpine Club Alpinist Magazine: Website | Instagram | Facebook Host: Abbey Collins Guest: Alan Rousseau Producer + Engineer: Mike Horn  

Find out all about Punakha River Lodge, &Beyond's new home-away-from-home in the kingdom of Bhutan. &Beyond Asia Managing Director Suhail Gupta talks about the challenges encountered and overcome during the building of the lodge. Renowned travel writer Gisela Williams shares warm and poignant memories from her first trip to Bhutan and delves deeper into the country's unusual model of tourism. &Beyond Sales & Touring COO Ryan Powell describes the emotions of being one of the first visitors to Punakha River Lodge and expands on how &Beyond plans to make a difference in local communities. 

Linda Bortoletto est exploratrice, conférencière, écrivaine, yogini et sillone en solitaire, depuis plus de dix ans, des contrées sauvages et spirituelles (Sibérie, Alaska,Himalaya,Israel,Andes) avec un objectif : éveiller les consciences. Un matin Linda décide de traverser Bali à pied sur la trace de ses ancêtres.  Elle prend une carte et voit une “grosse tache verte”, c'est là qu'elle veut aller au milieu de la jungle.  Après plusieurs recherches, elle ne trouve aucun sentier pour y accéder.  Tant pis, elle verra sur place. C'est comme ça que Linda voyage, à l'intuition, au ressenti. Dans cet épisode, Linda nous partage ses peurs, ses rencontres, ses conseils et comment le fait d'être ouverte à l'inconnu et l'inattendu lui a offert le plus challengeant, mais aussi le plus beau voyage de sa vie. Pour suivre Linda : www.lindabortoletto.com https://www.instagram.com/lindabortoletto Itw par Johanna : https://www.instagram.com/johannabros ----- 

🔸 PATREON GRATIS POR 7 DÍAS TE DEJO EL ENLACE https://www.patreon.com/checkout/prof... 🔹EPISODIO COMPLETO Y PARTICIPACION EN VIVO EN https://www.patreon.com/profesorbriceno 🔸 Las Grabaciones pueden verse en vivo en TWITCH https://www.twitch.tv/profesorbriceno (00:00:00) INTRO (00:00:43) MILEI REVIENTA ENCUESTAS (00:19:30) EL MENU (00:20:42) SHAKESPEARE CENSURADO y lo que te estás perdiendo (00:28:02) FÁRMACOS O HAMBURGUESAS (00:35:00) INYECCIONES FISCALES VS SUBIDAS DE INTERESES (00:39:36) COMO SABOTEAR LEYES (00:45:12) AJA POR FIN SABEMOS DE ESTO (00:53:45) UCRANIA VS LA CORRUPCIÓN (00:57:26) EL NEGOCIO DE LIMPIAR EL AIRE (01:05:12) AHORA ERES TÚ EN LA PELÍCULA (01:14:52 )EL SHERPA DE LA DISCORDIA (01:20:45) ECUADOR Y LA VIOLENCIA (01:24:15) NÍGER TIENE GAS Y PETROLEO PARA (01:25:58) COREA SE QUEDA SIN PEDIATRAS (01:29:20) EXTRA A QUIEN LE IMPORTAN LAS UNIVERSIDADES Sorprendente como hay quien aún se sorprenda de la victoria de Milei en las PASO de Argentina https://www.bbc.com/mundo/articles/crgngkd27zqo https://elpais.com/argentina/2023-08-13/elecciones-paso-2023-en-vivo.html Shakespeare censurado en Estados Unidos https://amp.elnuevoherald.com/noticias/florida/article278099687.html Los supresores de apetito amenazan a los vendedores de azúcar https://finance.yahoo.com/news/eli-lilly-beats-profit-estimates-105104058.html Los austeros vs los que quieren meter más real al sistema https://www.project-syndicate.org/commentary/us-soft-landing-not-the-feds-doing-fiscal-channel-interest-payments-debt-by-james-k-galbraith-2023-08 Así es imposible hacer democracia, ni siquiera dictadura https://www.kgw.com/article/news/politics/republican-walkout-10-senators-ineligible-measure-113/283-5354a1fa-b93f-43f2-afce-80a84d53666c Un médico venezolano nos echa un cuento del COVID y la ivermectina en el que confiamos https://www.youtube.com/watch?v=e2YGwykFSxI Ucrania peleando contra rusos y contra su corrupción https://www.theguardian.com/world/2023/aug/11/zelenskiy-sacks-all-military-recruitment-heads-over-frontline-bribes-scandal-ukraine Solo hace falta un trillón de dólares en capturadores de carbono para salvar al planeta https://www.technologyreview.com/2023/08/11/1077756/the-us-just-invested-more-than-1-billion-into-carbon-removal/ A quien le tienen que tener miedo los actores no es a la IA es a nosotros https://theconversation.com/what-are-hollywood-actors-and-writers-afraid-of-a-cinema-scholar-explains-how-ai-is-upending-the-movie-and-tv-business-210360 ¿Por qué nos preocupa un guía pakistaní muerto en el Everest? https://www.bbc.com/news/world-europe-66471990 Qué cambió en Ecuador https://www.aljazeera.com/news/2023/8/13/ecuador-gang-boss-who-threatened-villavicencio-moved-to-high-security-jail https://elpais.com/internacional/2023-08-13/ecuador-de-pais-tranquilo-a-uno-de-los-mas-violentos-de-la-region.html Por qué le seguimos parando a un golpe en Africa, cuando cada año hay tres. https://intellinews.com/niger-coup-threatens-nigeria-morocco-30bcm-gas-pipeline-project-286426/ https://www.spglobal.com/commodityinsights/en/market-insights/latest-news/oil/072823-niger-coup-could-jeopardize-oil-production-boost-create-regional-security-vacuum Cuando ya no solo escasean los niños sino también los pediatras, estás en Corea del Sur https://www.eldebate.com/familia/20230707/corea-sur-queda-pediatras-ante-tasa-natalidad-mas-baja-mundo_126495_amp.html#amp_tf=De%20%251%24s&aoh=16914541737915&referrer=https%3A%2F%2F Y EN EL EXTRA PARA QUÉ DIABLOS SIRVEN LAS UNIVERSIDADES https://www.msn.com/en-us/news/world/why-the-populist-right-hates-universities/ar-AA1eRzIc

DTO is an award-winning music producer, designing inspirational music that raises the vibrations of the planet.  DTO kicked off his career with a spark with his remix of “Love Me” by Grammy-nominated producer, StoneBridge.  DTO followed up with Nameless Energy, a yoga soundtrack recognized by Deepak Chopra for the kirtan project “Jai Ram” ft. Tara Devi. Nameless Energy is a music playlist guiding yoga instructors and students through a 60-minute yoga class. This album has integrated into the yoga world as an inspiring, healing, and transformational musical journey. --- On today's episode, Dave and I talk about how he discovered his Soul Purpose as a musician and the many things he learned about himself and about the world along the way. We discuss the power of frequency and how music (and all that we consume in our external world) impacts our body, mind and Soul. Dave shares about how he has disconnected from traditional North American society in a recent move to Costa Rica and, in doing so, more deeply connected to himself, his musicality and the essence of community and Mother Earth. --- If you'd like to find more of Dave, you can check out his website: https://dtomusic.com/ His music can be found anywhere you love to listen by searching "DTO" (Spotify link to the song used for this episode's intro breathwork & tune-in practice HERE ) And if you'd like to learn more about the incredible retreat centre Dave and his beautiful partner Himalaya facilitate at their STUNNING property in Costa Rica, you can find info below: Embody Costa Rica ---

Der Tod eines Bergträgers am K2 wirft viele Fragen auf über das Geschäft mit den Extrem-Besteigungen im Himalaya. Außerdem: Der Putsch im Niger – wie wahrscheinlich ist ein Einmarsch der Nachbarländer? (15:00)Tobias ArmbrüsterDirekter Link zur Audiodatei

Me seguís porque queréis saber qué cosas pasan en el lugar donde pasan las cosas. Y en China están pasando muchas cosas, más allá de lo que sale por la tele. Y quizá una de las cosas más importantes que esté pasando no sea una guerra en la periferia de Europa, algo que ocurre desde 2014 y jamás nos importó, ni siquiera la reordenación de los contratos de gas y petróleo a nivel mundial, el cambio de hegemón, inevitable, o las transformaciones que se avecinan si variamos los papelitos que llevamos en la billetera o incluso el formato que utilizamos para intercambiar bienes y servicios. Quizá una de las cosas más importantes que está sucediendo es la batalla por el agua en una región. Ni siquiera hablo de toda Asia, hablo de un trocito de Asia, una frontera en el Himalaya, frontera de China, India, Pakistán, Nepal, más Bangladesh y Myanmar que suponen, sólo esos 6 países, casi la mitad de toda la población mundial.

Intro: Hello, and welcome to episode 153 of the Childless not by Choice Podcast. My name is Civilla Morgan. My mission is to recognize and speak to childless not by choice women and men around the world, reminding you, us, that we can live joyful, relevant, fulfilled, childless not by choice, lives.   Whether you have children or not, thank you for tuning in!     Welcome to my eight-year podcastiversary!  What is today's show about? My Eight-Year Podcastiversary!   Thank you Patreon contributors: I would like to take a moment to say a special thank you to the people who make a financial contribution to the platform on a monthly basis, my Patreon Contributors. Some of you have been donating/giving/contributing, for years!  Your contributions help pay my podcast producer, my podcast host, Zoom, where I interview most of my guests, etc. So thank you very much!        If you are not yet a Patron, visit patreon.com/childlessnotbychoice to set up your monthly contribution. No matter your giving level, I have a gift for you!   If you prefer to give via PayPal, you can find me there at booksbycivillamorgan@gmail.com.  Your contributions to the platform are greatly appreciated! Thank you!   https://www.patreon.com/Childlessnotbychoice   Questions or comments? Contact me at:   Email: Info@civillamorgan.com                                                  Or   Visit the website at www.childlessnotbychoice.net, look to the left on the home screen and click on the link below the telephone to leave me an up to 90-second voicemail. Body of episode:   Before we get started though, I want to give a heads-up to those who listen to the Childless not by Choice podcast on the Stitcher Podcatcher app. Unfortunately, Stitcher is going away effective August 29, 2023. They say you may listen on their sister app Pandora. Many of you may know Pandora as a music app which it is, but Pandora started hosting podcasts a few years ago.  If you use the Stitcher app, there are instructions in the app on how to export your shows so you don't have to go one by one searching from them in another Podcatcher app.    And as I always say, the Childless not by Choice podcast can be found on just about any podcatcher app including Apple Podcasts, Spotify, Overcast, Himalaya, Bullhorn, Google Podcast, you name it, the podcast is there!     Of course, if you have any questions about how to listen to the podcast, reach out in the Childless not by Choice Facebook Group, email me at civilla@civillamorgan.com, or Message me on social.    So, I want to talk to you for a few minutes about Milestones and Lemonade!   Milestone: I have been talking to you for eight years and I love it! A great big thank you to the long-time listeners! And a great big welcome to all of the new listeners! I'm so happy you found us! If you have been listening since the beginning, you have been journeying with me through episodes where I had fabulous guests. Times of Me only episodes, aka monologue episodes. You stayed with me through my grief at the loss of my mommy, and you have continued with me as I continue to care for my dad. You've journeyed with me by listening to the episodes that I created to help you on your journey, but you have given me grace for my journey. Thank you.     Lemonade. I love lemons! The nice, fresh, ripe lemons that you roll on the kitchen counter a few times before cutting them in half and squeezing them to make lemonade, or squeezing them on seafood to create another level of flavor!  But life's lemons are a whole ‘nother story right?!   What lemon or lemons are you dealing with right now? We all get lemons in this life. And I believe although the lemon fruit adds another level of taste to many dishes, including lemonade, life's lemons can feel harsh. Breathtakingly so sometimes. Until you turn them into lemonade. Remember, life is filled with choices. Unless you decide, choose, to make the best of the life you have been given; the childless not by choice life, things can become, and stay overwhelming for a very long time. Who wants that? Life is too short. Do the best you can with where you are, how you are, and when you are. Most of us don't have full control over our jobs, our family members, where we live, etc., but whatever you can control, or manage, do. It will be good for your mental health. What is also good for your mental health is also to know the difference between what you can control and what you cannot.    PIVOT   Milestone. The first time I interviewed a man on the podcast was back in 2015! Link in the show notes! I couldn't believe I had not considered men. It was a whole different conversation. Of course right? Please listen to the episode! https://21stcenturyhannah.libsyn.com/childless-not-by-choice-from-a-mans-point-of-view-with-fellow-podcaster-dr-vibe Episodes with authors–I searched through the back catalog and found about seven episodes where I had the great opportunity to interview authors who have written on the subject of childlessness. If you have not listened to the back catalog, why not give it a try? I'm saying that knowing full well, like most podcasters, that our earlier work can feel cringe to us, but hey, it also shows how the show has matured.    Speaking of: It's OK to re-listen to an episode. Just like we re-watch certain movies or shows, we can re-listen to a podcast episode. I notice that every time I have re-watched or re-listened, I catch something I missed the first time. Now, in full transparency, every time you listen, that is a download for me. But honestly, if downloads were all I cared about, I would have quit podcasting a long time ago. There's a show I watch that is now in its seventh season! I have re-watched most of the episodes multiple times. And I am always shocked at what I missed the first or even the second time I watched. I guess it depends on what we may have been doing, aka multitasking, the first or second time we watch or listen to something. Also, an episode may affect you differently now, than it did when it first came out. So there's that!    Lemonade. I want to re-visit patronage and giving: If you find value in the content. If the podcast has helped you in any way, consider giving/contributing. I would like to continue creating this podcast, and regardless of the contributions, I will continue. Honestly, if I ever stopped the podcast it would not be because of the finances on the platform. It would be because it is time. But being able to use your contributions to pay for things on the platform, is so cool! Once again, to those of you who give regularly, thank you!  If you have been thinking about it but just have not gotten around to it, why not sign up during this time of my podcastiversary celebration? It would be truly appreciated. While I am asking, would you consider leaving a review at Apple Podcast to help bring recognition to the podcast? Anything you can do to help bring recognition to the podcast would be greatly appreciated!     Once again thank, thank you for being here. I see you, I think of you, you are worthy, you are here for a reason. You are fabulous! Don't forget that! Here's to another eight years. Cheers!   Special thank you to: Everyone who listens to the podcast! My contact information: Website: www.childlessnotbychoice.net and www.civillamorgan.com Facebook: booksbycivillamorgan Twitter: @civilla1 Instagram: @joyandrelevance Pinterest: Civilla M. Morgan, MSM LinkedIn: Civilla Morgan, MSM https://www.teepublic.com/stores/childless-not-by-choice

Welcome to The Challenges of Faith Radio Program. I ask that you listen, ponder, apply, and pray.....Also ask God for guidance, on how your gift(s) should be used in the public square for Him, and others..that are hurting, helpless, homeless, and feeling  hopeless. As you sojourn thru 2023, Remember, Life is like a coin, You can spend it any way you want to. But, you can only spend it once. So, spend it wisely! COFRP airs on: BTR, Edifi Christian Channel, iHeart, TuneIn , and TS Radio, Spotify, Apple, Audible, Google, Himalaya, Audacy, Wisdom, Podbay FM,Podbean, Listennotes.com, Podyssey, and YouTube:http://youtube.com/@COFRP COFRP http://challengesoffaithradioprogram.com Fyyd Radio: https://fyyd.de/podcast/challenges-of-faith-radio-program/0 COFRP: http://wavve.link/cofrp

Krish grew up in the shadow of the Himalaya's. As the oldest son within a Nepalese family, his responsibility within the Buddhist culture meant that he became a monk. He later attempted to join the Brigade of Gurkhas but failed. He tried again a year later and was successful. Later on he was the first Gurkha to pass selection and became a member of the Special Air Service.  Krish spent the next 19 years within the regiment rising to the rank of Warrant Officer. During that time he became the leader of mountain troop, training his fellow SAS soldiers. He is a world renowned mountaineer and has lead many record breaking expeditions. After leaving the military in 2021 he now spends his time as a spiritual guide and continues to take injured veterans into the mountains. His website can be found here

Tras dos días de bloqueos en la Autopista del Sol y varios puntos de Chilpancingo, los manifestantes y el gobierno llegaron a un acuerdo y se descongestionó la zona. ¿Cuál era el motivo de la protesta? La liberación de dos presuntos miembros del grupo criminal Los Ardillos. Cinco integrantes de una familia originaria de Monterrey, México fallecieron en la Cordillera del Himalaya luego de que el helicóptero en el que viajaban se estrelló cerca del Everest. Además… Movimiento Ciudadano insiste que no se sumará a la alianza de Va por México; la OTAN relajó las medidas para que Ucrania entre al club; y regresaron las protestas a Israel por la reforma judicial. Para enterarte de más noticias como estas, síguenos en nuestras redes sociales. Estamos en todas las plataformas como @telokwento. Hosted on Acast. See acast.com/privacy for more information.

AccuWeather Daily brings you the top trending weather story of the day - every day.

Join us as we dive into the captivating story of Rachael Crewesmith, an extraordinary mountaineer, rock climber, hill walker, and mountain bike guide. Discover how Rachael fearlessly defies boundaries in a male-dominated industry, taking on epic challenges and inspiring others along the way. Rachael in her own words:  “I'm a mountaineer, rock climber, hill walker, mountain biker and occasional paddler. I divide my time between the sprawling Scottish Highlands and the compact but wild mountains of Snowdonia where I work as a mountaineering instructor and mountain bike guide. I have ridden my bike across Nepal, round and round the Strathpuffer 24 hr endurance course and down the twisty, rooty trails of the forests of the Highlands. I have climbed up 100 Munroes (and counting), El Capitan in Yosemite, to 6000m in the Himalaya and up the north face of Ben Nevis. My favourite day out ever was climbing The Original Route on The Old Man of Hoy, on Orkney.  I've also spent time just travelling for travelling sake, especially in Asia. I visited Burma (Myanmar) at the same time as President Obama and witnessed the carnival of the first US state visit ever. I have walked across the living root bridges of Cherrapungee in north-eastern India and ridden the Darjeeling steam train. I have had dinner with the Nepali Army in Bhojpur and breakfast with the monks of north-eastern Thailand. I love coming home to the UK and realising just how amazing our diverse country is. From laverbread in South Wales to fresh mussels cooked in a jetboil on a Hebridean island, I love our country and all it has to offer.”   Get ready for an exciting month of July on the Tough Girl Podcast, as we shine a spotlight on women working in the outdoors. Sponsored by Land & Wave - join us as we delve into their stories, gain insights, and discover valuable tips from their incredible experiences.  Don't miss out on these empowering episodes released every Tuesday and Thursday at 7am UK time - hit the subscribe button and be part of the adventure!   Show notes Who is Rachael Working as an outdoor professional  Living in Llanberis in North Wales Where her love of the mountains comes from  Being obsessed with hockey from a young age Being inspired by her mum - who has previously swum the English Channel! Having a year out between school and university  Spending time in Nepal and going to Everest Base Camp at 18 Meeting a boy who was into climbing Joining the mountaineering club at Nottingham University  Why climbing didn't come naturally to her Studying archeology at university  Working as a hockey coach Leaving university and getting a job at a climbing wall Not having a plan in her career Not knowing what she wanted to do  Becoming a Rock Climbing Instructor (RCI)  Following up and doing her Mountaineering Climbing Instructor (MCI)  Becoming a Mountain Leader (ML) and doing 40 qualifying days  Loving the variety of what she can do with her qualifications  The challenges of working in the outdoor industry Making the transition to becoming a freelancer Why it's important to build connections and networks Getting work  The advantages of being a women in the outdoors Elitism in the industry Observing other women working in the industry Working with certain choice companies and what she's looking for Pay in the industry as a mountaineering instructor and mountain leader Asking for more money and being paid what your worth Favourite type of work to get  Remaining positive when dealing with miserable weather while out working Professional enthusiasm! Winter Mountain Leader Qualification  10% of Winter ML holders are female Association of Mountaineering Instructors (AMI) Women in Mountain Training Conference 2022 The importance of networking  Proximal Role Models - Rebecca Williams  Women's Trad Festival  Irish Women's Rock Festival  Advice for women who want to gain more qualifications Dr. Will Hardy - completion rates of Mountain Leader Qualification  Bangor University and Mountain Training PhD - Developing excellence in outdoor provision: enhancing training pathways for outdoor qualifications.  Why you should practice with a variety of people  Tips for finding people to train with  Women in Mountain Training Facebook Page Climbing the ‘Old Man of Hoy' part of the Orkney archipelago off the north coast of Scotland. What VS means in climbing - Very Severe  An explanation of traditional climbing grades Balancing the job/work with your love/passion for the outdoors Being able to pick and choose her work Being a Trustee of Cam&Bear Fund for Adventure  How to connect with Rachael   Wanting to run the Welsh 3000ers in under 12 hrs  “Think big, start small, but do start”   Social Media Website: rachcrewe.com  Instagram: @rachcrewe  Twitter: @rachcrewe Linkedin: www.linkedin.com/in/rachael-crewesmith-75211530/    

Der Nanga Parbat ist wie ein Brennspiegel der deutschen Geschichte - und Schauplatz eines dramatischen Alleingangs: Am 3. Juli 1953 erreichte der Tiroler Hermann Buhl als erster Mensch den Gipfel des "Killer Mountain" im Himalaya. 2003 hat Georg Bayerle seine Geschichte erzählt - mit einmaligen Originalaufnahmen.

Confira neste episódio, com participação do Dr. Ricardo Carvalho e do Dr. Antonio C. Buzaid, uma discussão sobre os dados do estudo HIMALAYA, que levou à aprovação pela ANVISA de tremelimumabe e durvalumabe, uma combinação exclusiva com imunoterapia, no tratamento do carcinoma hepatocelular. Assista ao Vídeo-MOC completo, com uma revisão sobre o estudo. mocbrasil.com/blog/videos-moc/vol14num08/

Bernd Zangerl a bouldering legend from Austria. We talked about his early climbing and making the 2nd ascent of Dreamtime, some of his proudest FAs, how he recovered from a career-ending injury in 2016, his mindset for highballs, meditation and the power of the mind, believing in love, our impact as climbers, sustainability, and discovering world-class bouldering in the Himalayas.Check out The Nugget on YouTube:youtube.com/@thenuggetclimbingCheck out Crimpd!crimpd.comOr download the Crimpd app!Check out Athletic Greens!athleticgreens.com/NUGGETUse this link to get a free year's supply of vitamin D + 5 travel packs!Check out Rocky Talkie!RockyTalkie.com/NuggetUse this link to get 10% off your first order of backcountry radios!Check out Rumpl!rumpl.com/nuggetUse code "NUGGET" at checkout for 10% off your first order!We are supported by these amazing BIG GIVERS:Leo Franchi, Michael Roy, David Lahaie, Robert Freehill, Jeremiah Johnson, Scott Donahue, Eli Conlee, Skyler Maxwell, Craig Lee, Mark and Julie Calhoun, Yinan Liu, Renzollama, Zach Emery, and Brandt MickolasBecome a Patron:patreon.com/thenuggetclimbingShow Notes:  thenuggetclimbing.com/episodes/bernd-zangerlNuggets:0:04:02 – Where we each are in the world, and Bernd's travels to the US0:05:15 – Magic Wood, and the impact climbers have on the environment0:08:02 – How to pronounce Bernd's name0:08:53 – Bernd's background in climbing, a near miss in the mountains, and falling in love with bouldering0:13:21 – The impossibility and culture of bouldering0:15:00 – “Bouldering is the kindergarten, but also the pinnacle of climbing.”0:16:50 – Dreamtime (8C), and learning about hard boulders by reading magazines0:21:25 – Reducing boulders to each single move, and holding positions for training0:24:41 – The bouldering culture in the early 2000s0:27:29 – Finding the most pure motivation in finding and developing new boulders0:29:22 – Spending eight years and 1000+ tries to send First Try (8B+)0:34:02 – What he learned from First Try0:38:56 – Nalle on Burden of Dreams, and the randomness of bouldering0:39:43 – Sending La Proue (8B) in Cresciano, and lightness of the heart0:41:20 – Openness of the heart, Buddhism, and believing in love and the good things of life0:42:57 – Bernd's childhood, and why traveling is important to him0:44:29 – Traveling with Fred Nicole to Hueco Tanks and Rocklands0:48:00 – Feeling and knowing0:49:41 – Developing boulders in the Himalayas, and finding Rakchham0:57:17 – Why Bernd decided to publish a film about Rakchham, and what it's like to travel there1:04:06 – Sustainability1:08:39 – How internet changed traveling1:10:34 – Disconnecting1:11:52 – Shangri-La1:13:29 – Working on a guidebook for Rakchham, when to go, and plans to go back1:16:04 – Getting the locals interested in climbing1:20:41 – Bernd's projects in Rakchham, and the potential and rock types1:25:06 – Doing the FA of Shantaram in Norway1:34:05 – Patron question from Simon, and Bernd's serious injury in 20161:39:41 – The healing power of the mind1:42:31 – Into the Sun, and Bernd's headspace for highballs1:50:39 – 29 Dots (14m/45' highball)1:58:45 – More about his recovery from his injury, and connecting of the East and the West2:03:53 – Bernd's advice, and brushing2:07:47 – Bernd's diet and lifestyle2:10:39 – Meditation2:14:59 – Bernd's unique approach to warming up and finger training2:23:50 – Shake, shake the body2:25:31 – Being pulled into the present

• Literatur • Was hat der „Maier am Himalaya“ mit Karl Marx oder Denis Diderot mit Edward Lear oder Margaret Thatcher zu tun? Was verbindet Kuba, Kometen, Poeten mit Pflanzenforschern und Mathematikern, Chefökonomen mit Cocktailrezepten?Von Hans Magnus Enzensbergerwww.deutschlandfunkkultur.de, HörspielDirekter Link zur Audiodatei

Washington y Beijing acuerdan estabilizar sus relaciones, mientras la Casa Blanca le ofrece una cena de estado a Narendra Modi, primer ministro de India, país que mantiene una disputa territorial con China en la frontera del Himalaya. En qué consiste la estrategia de EEUU hacia China?

It is nothing but a long summer trip thru Asia...

Pyritz, Lennartwww.deutschlandfunk.de, Forschung aktuellDirekter Link zur Audiodatei

Im Kampf gegen den Klimawandel wollen Deutschland und China nun zusammenarbeiten. Trotz politischer Differenzen. Die beiden Länder haben gestern eine entsprechende Absichtserklärung unterschrieben, bei einem Treffen zwischen Bundeskanzler Scholz und dem chinesischen Ministerpräsidenten Qiang. Weitere Themen: * Der Konflikt im Sudan hat enorme Auswirkungen auf die Menschen. Seit April wurden über zwei Millionen Menschen vertrieben. Hunderttausende sind in Nachbarländer geflüchtet beispielsweise nach Tschad. Dort hat sich die Situation in den letzten Tagen verschärft, denn der Tschad erlebt einen massiven Ansturm von Geflüchteten. * Der Klimawandel schmelzt nicht nur die Schweizer Gletscher, sondern auch die im Himalaya – und das in einem Tempo, das Forscherinnen und Forscher beunruhigt. Zwischen 2011 und 2020 sind die Himalaya-Gletscher um 65 Prozent schneller geschmolzen als im Jahrzehnt davor. * Saudi-Arabien investiert viel Geld in den Fussball – auch diesen Sommer wieder. Der französische Top-Stürmer Karim Benzema wechselt in die saudische Liga. Er soll dort jährlich rund 100 Millionen Euro verdienen. Letzten Winter hat bereits der mehrfache Weltfussballer Cristiano Ronaldo an den Golf gewechselt.

Pour vous abonner à nos 300 émissions hebdomadaires d'une heure sans publicité pour seulement 2€ par mois, avec une nouvelle émission chaque jeudi rien de plus simple, cliquez ici : https://m.audiomeans.fr/s/S-tavkjvmo Les uns se sont lancés dans la conquête des pôles et des étendues glacées tandis que d'autres sont partis à l'assaut des terres inviolées de l'Himalaya. Voici l'histoire, parfois légendaire, parfois méconnue, toujours romanesque, de l'exploration des neiges et des glaces. Voyageurs, géographes, alpinistes, soldats, missionnaires, scientifiques, écrivains, aventuriers, sportifs, diplomates ou baroudeurs, ils ont tous été des femmes, des hommes au caractère bien trempé, trait courant chez ceux qui aiment à vivre dans les mondes sauvages, à abhorrer le principe de précaution, à flirter avec le risque et à vivre avec intensité et gourmandise. Tous partagent ce goût pour l'ailleurs, la découverte, les autres, la liberté et l'absolu. Ils ont été courageux, rêveurs, héroïques, modestes, mystiques ou inconscients, voire épris d'idéaux. Cet ouvrage leur rend hommage, eux, les explorateurs des neiges et des glaces, des sommets et des pôles, eux, les explorateurs du « blanc dehors ». Stéphane Dugast, l'auteur, est de nouveau dans Xpresso, pour nous parler de son livre

Die Welt bangt um die Crew der "Titan", die auf ihrem Weg zur "Titanic" verschwunden ist. Die Welt sollte bangen, weil das Eis auf dem höchsten Berg der Welt sehr schnell schmilzt. Und den deutschen Fußballfans wird ganz bang beim Anblick des EM-Maskottchens. Das ist die Lage am Dienstagabend. Die Artikel zum Nachlesen: Was über die Besatzung des Tauchboots bekannt ist Rettungsmission in knapp 4000 Meter Tiefe Himalaja-Gletscher schmelzen schneller als in vergangener Dekade Der Bärendienst Mehr Hintergründe zum Thema erhalten Sie bei SPIEGEL+. Jetzt für nur € 1,– im ersten Monat testen unter spiegel.de/abonnieren.  +++ Alle Rabattcodes und Infos zu unseren Werbepartnern finden Sie hier: https://linktr.ee/spiegellage +++ Die SPIEGEL-Gruppe ist nicht für den Inhalt dieser Webseite verantwortlich.Mehr Hintergründe zum Thema erhalten Sie bei SPIEGEL+. Jetzt für nur € 1,– im ersten Monat testen unter spiegel.de/abonnieren Informationen zu unserer Datenschutzerklärung

Tây Tạng là một khu vực cao nguyên tại châu Á, ở phía bắc và đông của dãy núi Himalaya. Đây là quê hương của người Tạng cũng như một số dân tộc khác như Môn Ba, Khương, Lạc Ba, và hiện nay cũng có một số lượng đáng kể người Hán và người Hồi sinh sống. Kề liền với dãy núi thiêng Himalaya ở phía Tây Nam, Tây Tạng được coi là một trong những vùng đất linh thiêng và huyền bí nhất của thế giới, là thánh địa kiên cố cuối cùng của Phật giáo. Chính trên vùng đất này, Phật giáo từ lâu đã đi sâu vào tâm hồn, vào tất cả mọi sinh hoạt của người dân Tây Tạng, từ lúc chào đời cho đến lúc chết đi, từ tâm tư cho đến ngôn ngữ, lời nói, cử chỉ, tất cả đều thấm đẫm tinh thần từ bi của Phật giáo. Bởi vậy, nói đến văn hóa Tây Tạng, tức là nói đến văn hóa Phật giáo Tây Tạng, vì như thế mới có thể nắm bắt được cốt tủy của văn hóa Tây Tạng, và cũng chỉ như thế mới có thể khắc lên được một diện mạo hoàn hảo của văn hóa Tây Tạng.Hy vọng là sau khi hoàn thành sách nói Tây Tạng Huyền Bí Và Nghệ Thuật Sinh Tử, chúng ta sẽ có thể mường tượng ra một bức tranh rõ nét hơn về một vùng đất có thể nói là huyền bí nhất trên Trái đất. Chúng ta cũng sẽ hiểu hơn về bản chất vô thường của cuộc sống, về mỗi giây phút chúng ta hít thở và được chiêm ngưỡng ánh Mặt trời, về ý nghĩa của sự sống và cái chết. Trong cách nhìn thoáng đãng và dung dị của người Tây Tạng, cái chết không chấm dứt gì cả: nó mở ra cho chúng ta những cuộc phiêu lưu bất tận…--Về Fonos:Fonos là Ứng dụng âm thanh số - Với hơn 3.000+ nội dung gồm Sách nói có bản quyền, Ebook, Tóm tắt sách, Thiền định, Truyện ngủ, Nhạc chủ đề, Truyện thiếu nhi. Tất cả chương 1 đều miễn phí, tải app ngay: https://fonos.link/PCFonos--Tìm hiểu thêm về Fonos: https://fonos.vn/Theo dõi Facebook Fonos: https://www.facebook.com/fonosvietnam/

les invitamos a que nos escuchen en las siguientes plataformas digitales. Apple Podcast: https://podcasts.apple.com/us/podcast/alabanzas-adoraci%C3%B3n-y-predicas/id1464019350 Google podcast: https://podcasts.google.com/feed/aHR0cHM6Ly93d3cuc3ByZWFrZXIuY29tL3Nob3cvMTMwNTMxOS9lcGlzb2Rlcy9mZWVk?ep=14 Amazon music: https://music.amazon.com/podcasts/3c6fb15e-3c89-48d3-83d5-2e74ad62877b/alabanzas-adoraci%C3%B3n-y-predicas iheart: https://www.iheart.com/podcast/269-alabanzas-adoracion-y-pred-99664212/Spotify: https://open.spotify.com/show/5MEr3HT4j7aAOPqJRubmDE?si=J2zCWYE5T6GqTdqAQ8D2ig&utm_source=copy-link Audible: https://www.audible.com/pd/ALABANZAS-ADORACION-Y-PREDICAS-Podcast/B08K575KZZ Tunein: https://tunein.com/podcasts/Religion--Spirituality-Podcasts/Alabanzas-y-Adoracin-p1391909/ Spreaker: https://spreaker.page.link/imzCFVJ2G3tS7PabA Castbox: https://castbox.fm/channel/- Podbean: https://www.podbean.com/pa/dir-4cat9-94574 Podcast Addict: https://podcastaddict.com/?podId=2459792 Deezer: https://www.deezer.com/us/show/589422 Podchaser: https://www.podchaser.com/podcasts/alabanzas-adoracion-y-predicas-857912 Podbay: https://podbay.fm/p/alabanzas-y-adoracion Backtracks : https://backtracks.fm/discover/s/alabanzas-adoracion-y-predicas/a585f6d29d18567cJioSaavn: https://www.jiosaavn.com/shows/alabanzas--adoraciOn--y-predicas/1/OaiJVRu4HIc_ Emisoras colombianas: https://www.emisorascolombianas.co/podcasts/alabanzas-y-adoracionPoddtoppen: https://poddtoppen.se/podcast/1464019350/alabanzas-adoracion-y-predicasLiulu Fm: https://liulo.fm/show/alabanzas-adoracion-y-predicas-ch60c72758d7479b3bf50bae26 Up United podcaster: https://up.audio/podcasts/itunes1464019350 Himalaya: https://up.audio/podcasts/itunes1464019350 Getpodcast: https://getpodcast.com/it/podcast/alabanzas-y-adoracionRadios Chilenas: https://www.radios-chilenas.com/podcasts/alabanzas-y-adoracion Radio Ecuador: https://www.radio-ecuador.org/podcasts/alabanzas-y-adoracion

Guest Appearance: (LouV TV) LOUIS VALENTINE IV Make sure to tune into “THEADUSHOW” only on YouTube.com . You can also STREAM this show on all STREAMING PLATFORMS like Apple Podcasts, Google Podcasts, Listen Notes, Spotify Podcasts, Himalaya, and many more Platforms Worldwide. All Platforms are available for download on the App Store or Google Play Store. STAY COOL. LIVE LIFE.  | STAY SAFE. STAY SECURED. Socials Instagram: @aduartist Twitter: @aduartist TikTok: @aduartist Pinterest: @aduartist1 Snapchat: aduartist --- Send in a voice message: https://podcasters.spotify.com/pod/show/aduartist/message

Der erfahrene Berg- und Skiführer Luis Stitzinger war alleine auf dem dritthöchsten Berg der Welt unterwegs. Seit Donnerstag wurde er vermisst. Nun gibt es eine traurige Gewissheit. Web: https://www.epochtimes.de Probeabo der Epoch Times Wochenzeitung: https://bit.ly/EpochProbeabo Twitter: https://twitter.com/EpochTimesDE YouTube: https://www.youtube.com/channel/UC81ACRSbWNgmnVSK6M1p_Ug Telegram: https://t.me/epochtimesde Gettr: https://gettr.com/user/epochtimesde Facebook: https://www.facebook.com/EpochTimesWelt/ Unseren Podcast finden Sie unter anderem auch hier: iTunes: https://podcasts.apple.com/at/podcast/etdpodcast/id1496589910 Spotify: https://open.spotify.com/show/277zmVduHgYooQyFIxPH97 Unterstützen Sie unabhängigen Journalismus: Per Paypal: http://bit.ly/SpendenEpochTimesDeutsch Per Banküberweisung (Epoch Times Europe GmbH, IBAN: DE 2110 0700 2405 2550 5400, BIC/SWIFT: DEUTDEDBBER, Verwendungszweck: Spenden) Vielen Dank! (c) 2023 Epoch Times

Seit 70 Jahren wird der Mount Everest im Himalaya, mit über 8800 Metern der höchste Gipfel der Welt, von Menschen bezwungen. Von Anfang an war die Tour am Everest ein potenziell tödliches Abenteuer. Seit 1921 sind über 300 Menschen gestorben beim Versuch, den Berg zu besteigen.Das Risiko schreckt die Menschen nicht ab, sich auf den Weg zu begeben. Im Gegenteil. In den letzten Jahren hat sich eine Art Massentourismus am Everest entwickelt, mit Folgen für Natur und Land.  Im täglichen Podcast «Apropos» blickt Sportredaktor Christian Brüngger zurück auf ein Jahrhundert Bergsteigen, auf moderne Auswüchse des Extremsports und tödliche Exzesse. Gastgeber ist Philipp Loser.Mehr zum Thema: Stürze, Staus und Eiseskälte: Die Everest-Besteigung in ZahlenMount Everest als Business: Die Sherpas übernehmen das Geschäft am BergDen Tagesanzeiger 3 Monate zum Preis von 1 Monat (19.-) lesen: tagiabo.ch

Dr. Shaalan Beg and Dr. Mohamed Salem discuss novel therapies in gastrointestinal cancers, including CAR T therapy and the CodeBreak-101 trial in mCRC, new advances in uHCC in the HIMALAYA trial, and an exciting update from the NAPOLI-3 trial in pancreatic cancer, ahead of the 2023 ASCO Annual Meeting.  TRANSCRIPT Dr. Shaalan Beg: Hello, and welcome to the ASCO Daily News Podcast. I'm Dr. Shaalan Beg, your guest host of the podcast today. I'm the vice president of oncology at Science 37 and an adjunct associate professor at UT Southwestern Simmons Comprehensive Cancer Center. My guest today is Dr. Mohamed Salem, a GI oncologist at the Levine Cancer Institute at Atrium Health. We'll be discussing key posters and oral abstracts in GI oncology that will be featured at the 2023 ASCO Annual Meeting.  Our full disclosures are available in the transcript of this episode, and disclosures of all guests on the podcast can be found in our transcripts at asco.org/DNpod. Mohamed, thanks for coming on the podcast today.  Dr. Mohamed Salem: Thanks, Shaalan.  Dr. Shaalan Beg: There's some interesting studies in colorectal cancer that I'd like to get us started with today. Abstract 3547 is titled “A Phase I Dose-escalation Study of GCC19 CAR T: A Novel Coupled CAR Therapy for Patients with Metastatic Colorectal Cancer.” What are your thoughts on the study? Dr. Mohamed Salem: Actually, this was a very exciting study to see coming out in GI cancer, especially colorectal cancer. As you know, CAR T made its way to the treatment of lymphoma and other heme malignancies. In fact, we saw a fascinating response and outcome using that technique and that niche in the immunotherapy module. The challenge we had was that we could not replicate this in solid tumors until very recently. I'm sure you had the same thing in your clinic, too. A lot of patients with GI cancer or colorectal cancer come to you and say, "Okay, why can't I have CAR T?" And the response was, "We don't know if it's effective or if it's going to work yet." Here at our center, we had a phase 1 study, I think that was looking also at CAR T and solid tumors, particularly prostate cancer. So that I think was very exciting to see that technology is making its way to the solid tumor. I was very pleased to see this CAR T study coming out from the work of our Chinese colleagues looking into this in the CRC space.  Obviously, as you know, in colorectal cancer, we made a significant advancement, but I don't think we made enough advancement yet, and especially for refractory patients, patients with refractory disease who have underwent multiple lines of therapy. And this study actually addressed the need for those patients. So in this study, that was a phase I escalation dose, very much is we looked at about 13 patients who had metastatic CRC, they had at least two lines of therapy. So in what we say is a "refractory setting," unfortunately for those patients, we don't have large treatment options. And they used two doses, the first dose and the second dose that was a little bit higher. And the interesting part is that they were able to see very nice responses on this patient population. In the lower dose, I think the response was the PFS was about 1.9 months. But when they went up on the dose, actually the PFS was 6.3 months, which I think in the refractory setting is very meaningful.   And also the median overall survival for the first group was 13 months, which in the refractory setting is something we don't see often, and the higher dose was 18 months, which was even better. So there was a trend that higher doses are perhaps more effective or have better efficacies than lower doses, but also in terms of side effects, actually patients were relatively able to tolerate it well, and there were no surprising adverse events. So again, yes, that's 13 patients in total. So it's a very small study, but like everything else, the proof of concept sometimes is the first step and it's very important to see that data to suggest that this technology now can be utilized in solid tumors and CRC, especially now there is an unmet need for those patient populations. I'm sure you and I will see a lot of patients at the clinic with good progress status, and just looking for the next option, and I'm glad to see that. Hopefully, we can continue to build on that work.  Dr. Shaalan Beg: Another key abstract in colorectal cancer is Abstract 3513, the CodeBreak 101 study. This is a phase 1b safety efficacy trial of sotorasib plus panitumumab and chemotherapy with FOLFIRI for previously treated KRAS-G12C mutated colorectal cancer. And this is a really important study because even though KRAS-G12C represents a minority of KRAS mutated colorectal cancer, we know that this treatment can cause meaningful improvement in disease for other cancers like non-small cell lung cancer. And when sotorasib was tested as monotherapy in colorectal cancer, it saw an objective response rate of 9.7% that increased to 30% when added to panitumumab.   So in this trial, they took sotorasib plus panitumumab and added it to chemotherapy to see how it's tolerated and what its effectiveness is going to look like. And they enrolled people who had more than one or more lines of prior therapy for metastatic disease. They treated 33 patients. The most common side effect was dermatologic, which is probably related to EGFR-based therapy, and they saw a confirmed overall response rate of 58%. Side effects are those that we look to expect with this specific regimen. I don't see any additional safety concerns here, but this can be a big step forward for KRAS-G12C-altered colorectal cancer. What do you think? Dr. Mohamed Salem: I totally agree. And again, it was very exciting to see that abstract and that result. I totally believe now, and I'm sure you would agree with me too, Shaalan, that we're moving from an era of one size fits all to a precision oncology and tailored treatment. And the fact now we have a treatment option for patients with a KRAS mutation is very exciting because before, we didn't have much that we can do about that mutation. So now it's not just a proof of concept. Now you're hitting that target with the chemotherapy and you're getting a 50% response rate. That's something interesting also to see for this patient population and as you highlighted as safety also, and the adverse event was not high and patients were able to tolerate it, which makes it more doable for us to use it. Dr. Shaalan Beg: Yeah. And one of the challenges in the precision oncology space, which I'm sure you're experiencing in clinic as well, are the real-world applications of precision oncology and the drop-offs that happen that are preventing us from universal precision oncology - meaning the drop-offs that we see on eligible patients receiving the appropriate genomic testing, those who have genomic testing receiving the appropriate treatment. And we've seen a couple of fairly high-profile studies that are describing this in non-small cell lung cancer where the rates are not as encouraging as we would want it to be, which to me, as a physician, makes me worried that there are people out there who we don't know are carrying these mutations or have these mutations, and it hasn't been acted upon.   And related to that, there is an abstract at ASCO23, which is Abstract 3602, that looked at the real-world rates of FDA-approved targeted therapy and immunotherapy for people with metastatic colorectal cancer. They used the VA's National Precision Oncology Program data to study the prevalence of these mutations and how many of the folks ended up receiving the treatment that would be appropriate for those mutations. And this is a very exciting study. They looked at 908 metastatic colorectal cancer patients who underwent genomic profiling, 81% were colon and the rest were rectal. They found that 34% of patients harbored NRAS, KRAS, BRAF mutations, 9.6% were TMB-high, 7.7% had BRAF V600E, and 5.6% were MSI-high, which kind of puts the overall actionable variant prevalence in colon cancer at 47% and for rectal cancer at 44%.  And then they went down to see amongst those 424 eligible patients, how many ended up on appropriate therapy. And these were their numbers: for MSI-high 70%, TMB-high 47%, NRAS, KRAS, BRAF, wild-type 38%, BRAF V600E 17%. So nearly 30% of patients with MSI-high colorectal cancer did not receive immune checkpoint inhibitor therapy, and again, other aspects in terms of EGFR use, and I know that there are other challenges that may affect the use of EGFR inhibitors in colorectal cancer, but it really begs the point on aspects related to implementation science, on getting the testing and acting on those results. And I'm curious to what you're seeing that's being done on these initiatives nationally.  Dr. Mohamed Salem: I totally agree with you, Shaalan. This is a big problem we're facing day in and day out because we struggle to find treatment options for our patients. And I think if we're missing patient with targetable or actionable mutations and we're not utilizing that, I don't think that's a good situation to be in. And I think that's just a group effort. You have to work with the pathologist, you have to work with your team at the clinic. And as an oncologist treating this patient, we have to pay close attention to those markers. And frankly, just look for them. At least  the ones that you know are going to have therapeutic implications.  I do also think patient advocacy has a huge role here and huge opportunities that they can contribute. I am sure you are familiar with the pancreatic study that was published by our colleague Mike Pishvaian in Lancet a year or two ago. I think he named it the Know Your Tumor Type. I think that should be the way forward now, not just for pancreatic but for any cancer. Patients should ask their oncologists what my tumor is. Is it MSI-high, is it KRAS-G12C, is it BRAF? Because it will affect the treatment. I think it's multi-layer and all of us should work in a cohesive manner to be able to not ever miss those markers which carry therapeutic potential.   Dr. Shaalan Beg: So moving on to hepatocellular carcinoma, Dr. George Lau and colleagues, they'll be sharing data from the phase 3 HIMALAYA study with hepatocellular carcinoma in the Annual Meeting that's Abstract 4004. And he looked at outcomes by occurrence of immune-related events for people who received tremelimumab and durvalumab. What are your thoughts on this study?  Dr. Mohamed Salem: This was a very interesting abstract to see. For a long time, we didn't have many treatment options in hepatocellular carcinoma. So, over the last two or three years now, I think we've made nice advancements in the therapeutic landscape. So, we have multiple options including immunotherapy which is very exciting for all of us to be able to utilize those powerful drugs in that disease. The question that comes out is who actually responds? Obviously, in HCC you don't have a lot of biomarkers like the immune therapy biomarkers like MSI-high and PDL-1, and TMB. It isn't really playing a huge role in HCC. So, as you know, the HIMALAYA study is a phase 3 study and examined the STRIDE regimen which is treme plus durva in the first line of patients with metastatic or unresectable HCC against sorafenib. And the outcome was in favor of the STRIDE regimen with improvement in OS response rate and duration of response and because of that, it became one of the standards of care for that disease. But Abstract 4004 is actually asking a very interesting question - whether immune-related adverse events can predict outcomes. Meaning like those patients who experience immune-related adverse events will likely do better compared to those patients who didn't experience immune-related adverse events or not. The idea of adverse events as a biomarker if you will, for efficacy is not new. I mean we saw that back in the renal carcinoma TKI, hypertension. People who had hypertension were more likely to have a better response. In the GI also there was some data suggesting that rash might be a biomarker in predicting response to EGFR. So the same question we're applying here - immune-related adverse events can function as a biomarker for efficacy for the immune system.  And there are some data out there in other tumors that may be the case, but I think at least to my knowledge in the HCC or GI, this was the first study to address that question. So just to remind our audience that the HIMALAYA was a phase 3 study using the STRIDE regimen as a frontline for patients with hepatocellular carcinoma, either unresectable or metastatic disease. And they compared the STRIDE which is durva-treme compared to the standard of care at that time was sorafenib. The primary endpoint was overall survival and they had secondary endpoint duration of response, response rate, and obviously adverse event.  The study was positive, it met its primary endpoint and OS was in favor of the STRIDE regimen compared to sorafenib. But that part of the abstract now is focusing mainly on those patients who had immune therapy and whether that was a STRIDE regimen or the third arm that durva alone treatment. And they're looking at those patients who had immune-related adverse events, and those who didn't have immune-related adverse events. So basically four groups of patients, the patient who had a STRIDE regimen, about 139 patients had immune-related adverse events, and about 249 didn't have immune-related adverse events. For the cohort who had durva alone, about 64 patients had immune-related adverse events, almost 300 patients had no immune-related adverse events.  And it was very interesting that at least in the STRIDE arm, those patients who experienced immune-related adverse events, their outcome was better than those patients who did not have immune-related adverse events. It's the same trend seen on the durva alone arm, but I think the number was very small to make a statistical value out of it. But I think at least in the STRIDE arm there was a suggestive trend toward the outcome of those patients who experienced immune-related adverse events. So I think this is in a way very interesting because we're always wondering if we give the same dose at least in immunotherapy like for everyone.   What I was wondering is if it's too much, too little, or just right. It's hard to know for sure. But perhaps in my opinion and just me trying to understand why, in my theory, maybe that's just an indication of patients receiving enough drugs and effective drugs that will translate into efficacy. But at the same time, I also wanted to just put a word of caution here because we don't want to see side effects as a good thing. I think we want to make sure that us as oncologists treating these patients and patients also don't see like it's good to have a side effect. Side effects associated with especially those grade 3 or 4 can be associated with significant problems and decreased quality of life. So, definitely should be looking at those side effects and be careful interpreting those data. But I think that is very interesting and I will look for more work on that.   Dr. Shaalan Beg: Let's move on to pancreatic cancer. We heard the results of the NAPOLI-3 clinical trial at GI ASCO and this year in ASCO 2023 we will hear the results of Abstract 4006 by Dr. O'Reilly that are presenting results of the 12 and 18-month survival rates from the study that compared NALIRIFOX or nano-liposomal irinotecan, 5-fluoro/leucovorin, and oxaliplatin versus nab-paclitaxel/gemcitabine for newly diagnosed pancreatic cancer patients. I'm interested to hear what you think about that study. Dr. Mohamed Salem: Thank you, Shaalan. So this also is a very exciting abstract to see, and anyone who treats pancreatic cancer patients realizes that, unfortunately, even in 2023, we don't have a lot of treatment options. And yes, I think over the last decade we're now talking about second-line and third-line, but yet we still don't have a lot of treatment options. So, having more options is always good. But the question now is how do you sequence those chemotherapy options? Most of us obviously use FOLFIRINOX in the first line or gemcitabine and paclitaxel in the first line. Until very recently– because we didn't have a head-to-head comparison– we couldn't tell patients for sure if one is better than the other. I think we had some assumptions, but it wasn't really proven. It was just a cross-trial comparison.  So, the fact is that now we have that phase 3 trial looking at liposomal irinotecan, 5-fluoro/leucovorin and the oxaliplatin comparing to nab-paclitaxel/gemcitabine. To me, that was actually very exciting because now, at least, I can see a triplet chemotherapy drug compared to a doublet chemotherapy drug. And as you mentioned, Shaalan, the first initial read was positive in favor of the triplet regimen compared to the doublet, which I think was an important message to give to our colleagues and all of us that if you can, obviously, the triplet comes with side effects, but if you can deliver the triplet, that's perhaps a better starting point for the treatment. But the study here, we're trying to get more read after more mature or more time-lapsing. So the initial study was initial read was positive. And I think this is good to see, too because it translates that even with a longer follow-up, we're still seeing the same benefit. So the OS rate in 12 months for the triplet was about 45% compared to 39.5% for the doublet, and the 18 months, a year and a half, was 26% compared to 19%. So, definitely, you can see an improvement in every single endpoint. OS in general was 11.1 months compared to 9.2 months, and PFS was also in favor of the triplet. So I think it's a message here to reinforce what we saw a few months ago in the initial presentation that, in fact, the triplet is associated with better outcomes if you can safely manage the toxicity and guide the patient through the process. Dr. Shaalan Beg: Well, thank you very much, Mohamed. This was a lot of fun. Thanks for sharing your valuable insights with us on the ASCO Daily News Podcast. Dr. Mohamed Salem: Thank you for having me and looking forward to the full presentation at the meeting. And please, if you haven't registered for the meeting yet, make sure you attend. It's a wonderful opportunity to learn from an expert in the field and also meet your colleagues and make new friends. I also want to take this opportunity to thank the ASCO Daily News Podcast team for taking the time, and also for our colleagues who reviewed these abstracts. This takes a lot of time and effort, and I think they're doing a wonderful job. So, thank you to all of them, and I'll see you all at ASCO.  Dr. Shaalan Beg: And thank you to our listeners for your time today. You'll find links to the abstracts discussed today in the transcript of this episode. I'll be back to cover late-breaking abstracts and other key advances in GI oncology after the annual meeting, so please join us for more key insights from ASCO 23 on the ASCO Daily News Podcast.  Finally, if you value the insights that you hear on the podcast, please take a moment to rate, review, and subscribe wherever you get your podcast.  Disclaimer:The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experiences, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's speakers: Dr. Shaalan Beg @ShaalanBeg Dr. Mohamed Salem @SalemGIOncDoc   Follow ASCO on social media: @ASCO on Twitter  ASCO on Facebook  ASCO on LinkedIn   Disclosures:  Dr. Shaalan Beg: Consulting or Advisory Role:  Ispen, Cancer Commons, Foundation Medicine, Genmab/Seagen Speakers' Bureau: Sirtex Research Funding (An Immediate Family Member): ImmuneSensor Therapeutics Research Funding (Institution): Bristol-Myers Squibb, Tolero Pharmaceuticals, Delfi Diagnostics, Merck, Merck Serono, AstraZeneca/MedImmune  Dr. Mohamed Salem: Consulting or Advisory Role: Taiho Pharmaceutical, Exelixis, Bristol-Myers Squibb, Exelixis, QED Therapeutics, Novartis, Pfizer, Daiichi Sankyo/Astra Zeneca Speakers' Bureau: Genentech/Roche, Taiho Pharmaceutical, Daiichi Sankyo/Astra Zeneca, BMS, Merck

Sie sind das einzige ausländische Paar, das seit über zehn Jahren in Bhutan lebt: Irja und Adrian von Bernstorff. Die Dokumentarfilmerin und der Jurist haben drei kleine Kinder. Die Familie liebt das Land im Himalaya - aber das Paradies ist es nicht.Riedel, Annettewww.deutschlandfunkkultur.de, Im GesprächDirekter Link zur Audiodatei

Der Mount Everest ist nicht nur der höchste Berg der Welt, sondern auch der schmutzigste. Die zahlungskräftigen Touristen, die seit den 1990er Jahren in Scharen den Gipfel erobern, machen Dreck. 2008 zieht die erste Bergsteiger-Reinigungstruppe los, um aufzuräumen... Autorin: Andrea Klasen Von Andrea Klasen.

Una flor maravillosa de una planta única. Un color fabuloso de una exótica especie. Buscamos debelar el misterio de su nombre y origen. ECDQEMSD podcast episodio 5528 La Señora De Las Plantas Conducen: El Pirata y El Sr. Lagartija https://canaltrans.com Noticias Del Mundo: Google es Dios - La Inteligencia Artificial lo afectará todo - Ron De Santis le compite a Trump - La actividad del Popocatéptl - Qué es el Ecuador - Preguntas para El Mariscal Antonio José de Sucre - La Batalla de Pichincha al borde volcán. Historias Desintegradas: Las tardes después de regar - Balcón cerrado - Autocultivo demandante - Plantando un pino - Qué planta es esa - Plantas vs Zombis - Justificando un robo verde - Centro de mesa con frutas de plástico - Universidad de Hamburgo -  Santos Lugares el barrio de Ernesto Sábato - La gloria en mi repisa de trofeos - El plástico nos desilusiona - La titulación - Tardé en meter los papeles - Un pez saurio en el Himalaya y más... https://www.canaltrans.com/ecdqemsd_podcast_2023/5528_la_senora_de_las_plantas.html En Caso De Que El Mundo Se Desintegre Podcast no tiene publicidad, sponsors ni organizaciones que aporten para mantenerlo al aire. Solo el sistema cooperativo de los que aportan a través de las suscripciones hacen posible que todo esto siga siendo una realidad. Gracias Dragones Dorados: https://www.canaltrans.com/radio/suscripciones.html

Ley 3 de 3 alcanza el respaldo constitucional, 17 Congresos ya la aprobaronDesarticulan call center dedicado a la extorsión y fraude en NezahualcóyotlEncuentran en el Himalaya fósiles de un ictiosaurio

Pada bulan Apri 2023 lalu, European Space Agency (ESA) mengeluarkan sebuah artikel bertajuk “Revealing invisible Himalaya glacier loss.” ESA mengulas hasil studi yang mengungkapkan bahwa pencairan gletser di Himalaya, sebagai salah satu akibat dari perubahan iklim, ternyata jauh lebih parah daripada yang selama ini diprediksikan. Penaksiran yang lebih rendah daripada fenomena yang sebenarnya terjadi (disebut ‘underestimation') dalam pemodelan perubahan iklim dan dampak ikutannya menyimpan ancaman tersembunyi bagi masa depan kehidupan. Jika target iklim yang kita punya sejak Kesepakatan Paris masih jauh dari kata tercapai, bagaimana jadinya bila proyeksi perubahan iklim yang dijadikan acuan ternyata meleset dan kita telah terlambat untuk berbenah diri? Sehingga, kualitas data yang digunakan untuk pemodelan iklim memegang peranan fundamental dalam menghasilkan proyeksi perubahan iklim yang lebih representatif dan akurat—sebab ”garbage in, garbage out.” Amando Lasabuda, geolog Indonesia yang berkiprah di UiT The Arctic University of Norway, berusaha untuk menjawab tantangan tersebut melalui penelitian paleogeografi yang berhasil memenangkan hibah 4,2 triliun rupiah dari Marie Skłodowska-Curie Global Postdoc Fellowship 2023. Dalam percakapan ini, Amando menerangkan signifikansi temuannya kelak bagi studi perubahan iklim. “Tanpa adanya paleogeografi yang kredibel, maka model iklim masa depan pun akan penuh dengan ketidakpastian,” jelasnya. #Endgame #GitaWirjawan #PerubahanIklim ------------------------ Berminat menjadi pemimpin visioner berikutnya? Hubungi SGPP Indonesia di: admissions@sgpp.ac.id https://admissions.sgpp.ac.id https://wa.me/628111522504 Playlist episode "Endgame" lainnya: Wandering Scientists The Take International Guests Kunjungi dan subscribe: SGPP Indonesia Visinema Pictures

Esto es HistoCast. No es Esparta pero casi. Continuamos en Asia para viajar al techo del mundo con motivo del 55º aniversario del establecimiento de relaciones diplomáticas entre España y Nepal. Ascienden con vosotros Lara Veramendi, @tamtamveramendi, @DeividNagan y @goyix_salduero.Secciones Historia: - Geografía - 7:44 - Historia - 1:04:22 - Geopolítica - 3:03:00 - Relaciones diplomáticas - 3:26:30 - Bibliografía - 3:39:32

Each year, thousands of men and women from around the globe flock to the Himalaya and the Karakoram in order to climb the world's tallest mountains. Despite being aware of a fatality rate as high as 29% (depending on the mountain), amateur climbers are willing to hand over $65K-$150K to “professional” guiding services to hopefully get them to the summit and back in one piece. While storms and avalanches at these elevations cannot be controlled, overcrowding can. Human traffic jams leading to these summits are directly responsible, or complicit, in causing high rates of death and injury. This year, 2023, more people have purchased permits to climb these 14 mountains than in any other year in history…

Each year, thousands of men and women people from around the globe flock to the Himalaya and the Karakoram in order to climb the world's tallest mountains. Despite being aware of a fatality rate as high as 29% (depending on the mountain), amateur climbers are willing to hand over $65K-$150K to “professional” guiding services to hopefully get them to the summit and back in one piece. While storms and avalanches at these elevations cannot be controlled, overcrowding can. Human traffic jams leading to the summits of these mountains are directly responsible, or complicit, in causing high rates of death and injury. This year, 2023, more people have purchased permits to climb these 14 mountains than in any other year in history…

Con nosotros, Rosa Fernández, montañera. La primera mujer española que completó el proyecto de subir a las 7 cimas más altas de los continentes. Asia, África, América del Norte, América del Sur, Europa, Oceanía y la Antártida. "Me surgió la oportunidad con un grupo de chicos de Asturias que tenía prevista una expedición al Himalaya". Aquella expedición se llamó "Siete cardos y una Rosa". Fernández. "No imaginaba lo que era una montaña de 8 mil metros. Fue la aventura de mi vida". "Luego pensé que podía subir el Everest. Y allí me fui". Escuchar audio

En el episodio #210 hice un especial llamado Viaje al fondo del alma, en el que te cuento las 7 lecciones de vida que aprendí en los Himalayas.Escalar una de las montañas más grandes del mundo es una experiencia única que te da la oportunidad de capturar el encanto de la naturaleza y del misterio de la vida. Fueron más de 180 kilómetros recorridos en 15 días, ascendiendo de 900 a 5,100 metros sobre el nivel del mar, llegando a temperaturas de menos 10 grados centígrados y estando completamente solo la mayor parte del tiempo.En cada paso tuve tiempo de agradecer, de estar presente, de desacelerar el ritmo de la vida, de descubrir una nueva cultura, de ahondar a nivel espiritual, de meditar en movimiento y a reconectarme con mi capacidad de asombro. Todos estos regalos me dejaron muchas enseñanzas súper valiosas, pero en este episodio te resumo la experiencia en las 7 lecciones más importantes que aprendí en mi expedición. No te pierdas los aprendizajes que traje para ti desde los Himalayas en un nuevo episodio de Máximo desempeño.

The BFM (Black Founders Matter) Fund's Himalaya Rao speaks with David Bank about the alpha case for racial justice investing and the challenges faced by a woman manager when raising her first fund. Our earlier VC Include interviews: https://impactalpha.com/toussaint-bailey-uplifting-capital-bringing-the-quietly-bothered-into-impact-investing-podcast/ https://impactalpha.com/bahiyah-yasmeen-robinson-on-includes-three-drivers-of-inclusion-alpha-podcast/ --- Send in a voice message: https://podcasters.spotify.com/pod/show/impact-alpha/message

Niall Grimes introduces top Himalayan climber of the 70s, 80s andf 90s, Al Burgess.

Nuestro viaje comienza en el Ártico, donde cada verano se desprenden enormes cantidades de hielo de los bordes de los glaciares que se derriten en Groenlandia. En la parte superior de la capa de hielo, el glaciólogo Alun Hubbard desciende a un moulin para tratar de comprender los mecanismos que están impulsando esta histórica pérdida de hielo. En otras partes del Ártico, no solo está desapareciendo el hielo terrestre. En el golfo de San Lorenzo, Canadá, los biólogos están tratando de averiguar cómo afectará la pérdida de hielo marino a la vida de las crías de arpa. En la Rusia ártica, con la pérdida del hielo marino del verano, cada vez llegan más osos polares a la isla de Wrangel. Aquí, un guardabosques local y científicos desafían a los osos hambrientos para evaluar su futura supervivencia. La pérdida de hielo marino afecta no solo a la vida silvestre sino también a las personas. En la remota comunidad de Qaanaaq, Groenlandia, los cazadores inuit locales encuentran que el hielo es demasiado peligroso para viajar y cazar, poniendo en riesgo su forma de vida tradicional. Y estos cambios que ocurren en el Ártico tienen el potencial de afectar a las personas mucho más allá. En la tundra abierta de Alaska, los lagos burbujeantes insinúan los gases que se liberan del suelo previamente congelado, incluido el metano, un potente gas de efecto invernadero. Hay un lugar donde se puede presenciar mejor la escala completa de un Ártico que se derrite: desde el espacio. Con base en la Estación Espacial Internacional, la astronauta Jessica Meir observa los incendios forestales en toda Europa y refleja cómo nuestros patrones climáticos cambiantes están interconectados. La rápida pérdida de hielo también está ocurriendo en las altas montañas de los continentes del planeta. El glaciólogo Hamish Pritchard utiliza un sofisticado sistema de radar instalado en un helicóptero para tratar de cuantificar cuánto hielo queda en los glaciares del Himalaya que antes no estaban cartografiados. Es importante ya que, río abajo, unos 1200 millones de personas dependen del agua de deshielo de los glaciares como fuente principal de agua dulce. Finalmente, en la Antártida conocemos a Bill Fraser, quien ha dedicado 45 años de su vida al estudio del pingüino Adelia. Durante este período, ha sido testigo de cambios en las condiciones climáticas y la extinción de colonias enteras. Estos 'canarios en la mina de carbón' son una señal de que no todo está bien, incluso en el lugar más remoto de la tierra. Y los cambios aquí tienen el potencial de afectarnos a todos, por lo que un grupo internacional de científicos se encuentra en una misión urgente para evaluar la estabilidad de una enorme masa de hielo conocida como la plataforma de hielo de Thwaites. Si este tapón de hielo se derrite y se desliza hacia el océano, elevará los niveles globales del mar, lo que afectará a las comunidades costeras de todo el planeta. Los cambios sin precedentes que nuestros científicos están presenciando pueden ser profundos, pero existe la esperanza de que, a través de una combinación de tecnología y fuerza de voluntad, todavía haya tiempo para salvar lo que queda de nuestro planeta helado.

Brahmagyan Ka Ye Satsang Himalaya Yogiyon Ko Durlabh Hai : Pujya Sant Shri Asharamji Bapu Satsang

Brahmagyan Ka Ye Satsang Himalaya Yogiyon Ko Durlabh Hai : Pujya Sant Shri Asharamji Bapu Satsang

HERE'S MY FULL CONVERSATION with Alan Arnette on YouTube:https://youtu.be/WIk67aEg0sIThere's Been Loss of Life and Intense Drama on Annapurna and in the Mount Everest and 8000 meter peaks region of the Nepal Himalaya. A veteran climber is dead, another miraculously rescued, and multiple others are lucky to be alive after a tragic few days in the Himalayas.As the deadliest of the 8000 meter peaks Annapurna has of late become an object of desire for a wider and larger group of the new era of mountaineers, ticking off peaks on their checklist.In recent years, guides have supplied high levels of support and supplemental oxygen to make the peak more accessible to less experienced climbers. Of the 395 total summits, 129 (33 percent) have occurred in the past three years.HERE'S AN INTERVIEW with one of the world's most respected chroniclers of Mount Everest, Alan Arnette WHO is reporting on this spring's Everest and Himalayan climbing season for OUTSIDE ONLINE We'll talk about the miraculous rescue effort on Annapurna where Indian climber Anurag Maloo was found alive after spending three days inside a crevasse on Annapurna. Angela Benavides of Explorers Web has reported that Maloo was 50 meters in the crevasse, found barely alive by a rescue team led by Adam Bielecki - mind boggling….defying all odds…hope to bring more on that soon.As well as the loss that sent shockwaves through the himalayan climbing community, the ever popular and 10-time Everest summiter, Noel Hanna of Ireland, 56, died in his tent at Camp 4 after summiting without supplemental oxygen. We also discuss the summit of Manaslu by Felix Berg, as well as the sherpas expanding role in the world of 8000 meter peak guiding. And Alan has written a book.YOU CAN FIND ALAN'S BLOG at alanarnette.com Support the show

Las esencias más puras no siempre se almacenan en frascos pequeños. La prueba está en el estado norteño de Uttar Pradesh, un vastísimo territorio en torno a las llanuras fluviales del Ganges y el Yamuna, los dos ríos más sagrados de India. En su capital, Lucknow, conocemos a Shubhangi Verma, una diseñadora gráfica casada con el periodista español Ángel L. Martínez Cantera. Su libro 'Al sur del Himalaya. Crónicas asiáticas' (editorial Kailas) nos permite adentrarnos en el alma de esta bulliciosa urbe. Además de conocer monumentos como Rumi Darwaza o Bara Imambara, recordamos la lucha por la independencia en el recinto de La Residencia. El guía local y youtuber Rizwan Khan nos muestra esa dura parte de la historia india antes de animarnos a conocer la artesanía y la rica gastronomía de su ciudad. Abandonamos Lucknow rumbo a Agra, Benarés y Allahabad, otros destinos imprescindibles de Uttar Pradesh. El director de la Casa de la India, Guillermo Rodríguez, la profesora de danza kathak Núria Cabo y el gerente del touroperador receptivo Diva India, Shariq Jamil, guían nuestros pasos por la región del Taj Mahal. Escuchar audio